Adaptimmune, a leader in T-cell therapy, is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies using its proprietary SPEAR T-cell receptor platform. This platform enables the engineering of T-cells to target and destroy cancer, by harnessing the body's own immune system to find and destroy diseased cells, to treat solid tumors. Adaptimmune is conducting clinical trials with SPEAR T-cells targeting MAGE-A4, MAGE-A10 and AFP across several solid tumor indications. Please visit www.adaptimmune.com or follow us on Twitter (@Adaptimmune).